

22 **Abstract**

23 **Objectives:** We report interim safety and immunogenicity results from a phase 3 study of
24 omicron-BA.1 variant-containing (mRNA-1273.214) primary vaccination series (Part 1) and
25 booster dose (Part 2) in children aged 6 months to 5 years (NCT05436834).

26
27 **Methods:** In Part 1, SARS-CoV-2 unvaccinated participants, including participants who
28 received placebo in the KidCOVE study (NCT04796896), received 2 doses of mRNA-1273.214
29 (25- μ g omicron-BA.1 and ancestral Wuhan-Hu-1 mRNA 1:1 co-formulation) primary series. In
30 Part 2, participants who previously completed the mRNA-1273 (25- μ g) primary series in
31 KidCOVE received a mRNA-1273.214 (10- μ g) booster dose. Primary objectives were safety,
32 reactogenicity, and immunogenicity, including prespecified immune response success criteria.

33
34 **Results:** At the data cutoff (December 5, 2022), 179 participants had received ≥ 1 dose of
35 mRNA-1273.214 primary series (Part 1) and 539 participants had received a mRNA-1273.214
36 booster dose (Part 2). The safety profile of mRNA-1273.214 primary series and booster dose was
37 consistent with that of the mRNA-1273 primary series in this same age group, with no new
38 safety concerns identified and no vaccine-related serious adverse events observed. Compared
39 with neutralizing antibody responses induced by the mRNA-1273 primary series, both the
40 mRNA-1273.214 primary series and booster elicited responses that were superior against
41 omicron-BA.1 and non-inferior against ancestral Wuhan-Hu-1(D614G).

42
43 **Conclusions:** mRNA-1273.214 was immunogenic against BA.1 and D614G in children aged 6
44 months to 5 years, with a comparable safety profile to mRNA-1273, when given as a 2-dose
45 primary series or as a booster dose after the mRNA-1273 primary series.

46
47 **Clinical Trial Registry:** NCT05436834

48

49 Introduction

50 mRNA-based vaccines have been an essential approach to mitigate COVID-19 burden
51 among children and adults worldwide.¹ However, with the predominance of immune-evasive
52 omicron sublineages globally,²⁻⁴ COVID-19 vaccines targeting the ancestral SARS-CoV-2 strain
53 have shown reduced effectiveness.^{5,6} A 2-dose mRNA-1273 primary series (SPIKEVAX;
54 Moderna, Inc., Cambridge, USA) was well-tolerated in children aged 6 months to 11 years in the
55 phase 2/3 KidCOVE trial, eliciting immune responses against the ancestral strain that were
56 noninferior to those in young adults.^{7,8} When the delta variant prevailed, the primary series
57 demonstrated 88.0% (95% CI, 70.0-95.8; modified intent to treat [mITT]) efficacy in children
58 aged 6-11 years.⁸ However, during omicron predominance, vaccine efficacy was 45.8% (95%
59 CI, 19.0-63.4; mITT) and 39.6% (95% CI, 19.1-54.6; mITT) in children aged 6-23 months and 2-
60 5 years, respectively.⁷ Consistent with clinical trial data, real-world effectiveness of 2 doses of
61 mRNA-1273 among children aged 3-5 years is reported at 36% (95% CI, 15-52) during
62 circulation of omicron sublineages.⁹ A higher infection and disease burden among children was
63 observed after the emergence of omicron, with COVID-19 now the leading cause of infectious-
64 and respiratory disease-related deaths among US individuals aged 0-19 years, surpassing
65 influenza and pneumonia.¹⁰

66 Accordingly, COVID-19 vaccination strategies have been devised to broaden protection
67 against SARS-CoV-2 variants. Variant-updated vaccines containing mRNAs encoding for both
68 the ancestral SARS-CoV-2 strain (as in mRNA-1273) and omicron subvariant BA.1 (mRNA-
69 1273.214) or BA.4/BA.5 (mRNA-1273.222) have been developed. In the United States, mRNA-
70 1273.222 is authorized as a booster dose among individuals aged ≥ 6 months and as a primary
71 series for age groups recommended to receive a primary series.¹¹ In individuals aged ≥ 16 years, a

72 booster dose of either variant-containing vaccine has elicited superior neutralizing antibody
73 (nAb) responses against the relevant omicron strain with a safety profile similar to mRNA-
74 1273.¹²⁻¹⁴ Given the consistent immunogenicity profile for the mRNA-1273 primary series
75 between pediatric populations and young adults,^{7, 8, 15} variant-containing vaccination could
76 provide similar benefits to children as seen in adults.

77 Here, we report interim safety and immunogenicity results from a phase 3 study of mRNA-
78 1273.214 primary vaccination series (Part 1) and booster dose (Part 2) in children aged 6 months
79 to 5 years, as a model for variant-containing COVID-19 vaccination in children.

80

81 **Methods**

82 *Study Design and Participants*

83 The open-label, phase 3 ROVER trial enrolled participants aged 6 months to 5 years at 24
84 US study sites and was conducted in 2 parts (NCT05436834; **Figure S1**). Part 1 enrolled
85 participants who were not previously vaccinated against SARS-CoV-2, including participants
86 who received placebo in KidCOVE (NCT04796896). Participants received 2 doses of mRNA-
87 1273.214 (25- μ g omicron-BA.1 and ancestral Wuhan-Hu-1 spike mRNA 1:1 co-formulation)
88 primary series on Days 1 and 29, with a 12-month follow-up period after dose 2. Part 2 enrolled
89 participants who previously completed mRNA-1273 (25- μ g) primary series in KidCOVE.
90 Participants received a mRNA-1273.214 (10- μ g) booster \geq 4 months after mRNA-1273 primary
91 series and were followed for 6 months after booster. Participants who completed mRNA-1273
92 primary series in KidCOVE served as a historical comparator for inference of mRNA-1273.214
93 vaccine effectiveness.

94 Eligible participants were generally healthy or had stable chronic conditions, without a
95 known SARS-CoV-2 infection in the preceding 90 days. Inclusion/exclusion criteria and study
96 ethical statements are described the **Supplement**.

97 The protocol and study documents were approved before conduct of study procedures
98 (Advarra Institutional Review Board). Written informed consent from parent(s)/legally
99 authorized representative(s) of children was obtained before performing study procedures.

100

101 *Vaccines*

102 mRNA-1273 contains mRNA encoding for the prefusion stabilized spike glycoprotein of
103 the Wuhan-Hu-1 isolate of SARS-CoV-2. mRNA-1273.214 contains mRNAs (1:1 ratio)
104 encoding for the prefusion stabilized spike glycoprotein of the Wuhan-Hu-1 isolate and for the
105 omicron variant (B.1.1.529) subvariant BA.1 protein and was administered intramuscularly as a
106 25- μ g primary series (Part 1; Days 1 and 29) or 10- μ g booster (Part 2; booster Day 1).

107

108 *Objectives*

109 The primary safety objective was to evaluate the safety and reactogenicity of mRNA-
110 1273.214 administered as a 2-dose primary series (25- μ g dose, Part 1) or as a single booster (10-
111 μ g dose after mRNA-1273 25- μ g 2-dose primary series, Part 2) in participants aged 6 months to
112 5 years. Primary immunogenicity objectives were to infer effectiveness of mRNA-1273.214
113 based on immune responses against SARS-CoV-2 strains BA.1 and Wuhan-Hu-1 (D614G)
114 measured 28 days after vaccination among participants (1) regardless of baseline SARS-CoV-2
115 status (Part 1) or (2) who completed mRNA-1273 primary series and were SARS-CoV-2
116 negative prior to booster (Part 2). Inference of mRNA-1273.214 effectiveness was based on

117 assessment of immune responses in participants in the same age group after mRNA-1273
118 primary series in KidCOVE. Secondary objectives are described in the **Supplement**.

119

120 *Safety Assessments*

121 Safety assessments included local and systemic solicited adverse reactions (SARs)
122 through 7 days after vaccination; unsolicited adverse events (AEs) through 28 days after
123 vaccination; and AEs leading to study withdrawal, medically attended AEs (MAAEs), AEs of
124 special interest (AESIs; **Table S1**), and serious AEs (SAEs) from Day 1 through the interim
125 analysis data cutoff.

126

127 *Immunogenicity Assessments*

128 Blood samples for immunogenicity assessments were collected on Days 1 and 57 (Part 1)
129 and booster Days 1 and 29 (Part 2). Samples on Days 1 and 57 after mRNA-1273 primary series
130 from KidCOVE participants were evaluated as a historical comparator. nAb geometric mean
131 concentrations (GMCs) against BA.1 and Wuhan-Hu-1 (D614G variant to optimize signal
132 detection) were measured using pseudovirus neutralization assays.¹⁶ Seroresponse rates (SRRs)
133 against BA.1 and D614G were evaluated.

134

135 *Statistical Analyses*

136 Sample size calculations are presented in the **Supplement**. Safety analyses were based on
137 the safety set, except for SARs which were based on the solicited safety set (**Table S2**). Part 1
138 primary immunogenicity analyses were assessed using the per-protocol immunogenicity set
139 (PPIS); this analysis set was chosen as it was representative of the high prevalence of

140 seropositivity among previously unvaccinated individuals. Part 2 primary immunogenicity
141 analyses were conducted among participants in the PPIS with no serologic or virologic evidence
142 of prior SARS-CoV-2 infection (PPIS-Neg).

143 nAb values with corresponding 95% CIs were calculated at each sampling timepoint.
144 Number and percentage of participants with seroresponse after vaccination were provided with
145 2-sided 95% CIs (Clopper-Pearson method). For the primary immunogenicity analysis of nAb
146 GMCs, a covariance model was utilized with the nAb value as the dependent variable and group
147 (mRNA-1273.214 vs mRNA-1273) as the fixed variable, adjusted for age subgroup (6-23
148 months and 2-5 years). The Part 1 model also adjusted for baseline SARS-CoV-2 infection status
149 (ie, evidence of prior SARS-CoV-2 infection). The nAb GMC value was estimated using the
150 model geometric least square mean (GLSM). The geometric mean ratio (GMR; mRNA-1273.214
151 vs mRNA-1273) was estimated using the ratio of GLSM, with 2-sided 95% CI from the model
152 employed to assess differences in immune response between the 2 groups. Superiority and non-
153 inferiority were declared if the lower bound (LB) of the GMR 95% CI was >1 and >0.667 ,
154 respectively. SRR analyses are described in the **Supplement**.

155

156 **Results**

157 *Part 1*

158 **Participants**

159 From enrollment to the interim analysis (June 21, 2022, to December 5, 2022), 179
160 participants received ≥ 1 dose of mRNA-1273.214 and 142 (79.3%) reached day 28 and received
161 dose 2 (**Figure 1**). Median (interquartile range [IQR]) age of participants was 3 (1-3) years and
162 most participants were White (65.4%; **Table 1**). Median (IQR) follow-up time was 85 (43-113)

163 days after dose 1 and 68 (34-90) days after dose 2. Baseline SARS-CoV-2 positivity rate was
164 63.1%.

165 **Safety**

166 At least 1 SAR within 7 days after dose 1 and 2 was reported by 102 (57.0%) and 89
167 participants (63.1%), respectively (**Figure S2**). Most SARs were grade 1 or 2; no grade 4 events
168 were reported. The most commonly reported local SAR after either injection was pain (51.4%).
169 Irritability/crying (55.2%), sleepiness (43.7%), and fatigue (41.8%) were the most commonly
170 reported systemic SARs. Fever ($\geq 38^{\circ}\text{C}/100.4^{\circ}\text{F}$) was reported by 16 participants (8.9%) after
171 dose 1 and 19 (13.5%) after dose 2. Grade 3 fever was reported by 2 participants (1.1%) after
172 dose 1 and 2 (1.4%) after dose 2. Median (range) time of SAR onset was 1.0 (1-5) and 1.0 (1-6)
173 day after doses 1 and 2, respectively, and duration was 2.0 (1-7) days after doses 1 and 2.

174 Unsolicited AEs were reported by 30.7% of participants within 28 days after either
175 injection; 1.1% were considered vaccine-related (1 report each of diarrhea and croup; **Table S3**).
176 The most common unsolicited AEs were upper respiratory tract infection (8.9%), rhinorrhea
177 (2.8%), and ear infection (2.2%). One participant (0.6%) experienced an SAE (asthma
178 exacerbation 14 days after dose 1) considered unrelated to vaccination. There were no AESIs or
179 AEs leading to discontinuation of study vaccine or study participation up to the data cutoff.

180 **Immunogenicity**

181 The primary series induced nAb levels against BA.1 that were superior to those elicited
182 by mRNA-1273 in KidCOVE (**Figure 2A**). Among the PPIS, observed nAb GMCs (95% CI)
183 against BA.1 were 1889.7 (1430.0-2497.2) after mRNA-1273.214 primary series and 74.3 (67.7-
184 81.7) after mRNA-1273. The Day 57 estimated GMR (95% CI) was 25.4 (20.1-32.1), meeting
185 the pre-specified superiority criterion. Among the PPIS-Neg, mRNA-1273.214 primary series

186 induced higher observed nAb GMCs (95% CI) against BA.1 than mRNA-1273 primary series at
187 Day 57 (mRNA-1273.214: 1037.9 [786.5-1369.7]; mRNA-1273: 65.7 [60.6-71.3]), with an
188 estimated GMR (95% CI) of 15.8 (11.4-22.0). Day 57 SRRs (95% CI) for BA.1 were 89.3%
189 (78.1-96.0) and 86.8% (82.0-90.7) after mRNA-1273.214 and mRNA-1273 primary series,
190 respectively (**Table S4**).

191 At Day 57, the primary series elicited nAb responses against D614G that were non-
192 inferior to those induced by mRNA-1273 primary series in KidCOVE (**Figure 2B**). Among the
193 PPIS, the observed nAb GMCs (95% CI) against D614G were 1432.9 (1054.5-1947.0) after
194 mRNA-1273.214 and 1732.5 (1611.5-1862.5) after mRNA-1273. The estimated GMR was 0.8
195 (95% CI, 0.7-1.0), meeting the pre-specified criterion of non-inferiority. Among the PPIS-Neg,
196 the observed nAb GMCs (95% CI) against D614G were 612.5 (448.2-836.9) after mRNA-
197 1273.214 and 1559.4 (1459.2-1666.6) after mRNA-1273, with an estimated GMR of 0.4 (95%
198 CI, 0.3-0.5). Day 57 SRRs (95% CI) were 97.0% (89.5-99.6) and 99.5% (98.5-99.9) after
199 mRNA-1273.214 and mRNA-1273 primary series, respectively (**Table S4**).

200

201 *Part 2*

202 **Participants**

203 From enrollment to the interim analysis (June 22, 2022, to December 5, 2022), 539
204 participants received a mRNA-1273.214 booster (**Figure 1**). Median (IQR) age was 3 (2-4; the
205 older age range reflecting the time lapse between primary series receipt in KidCOVE and
206 become eligible for booster dosing) years and most participants were White (81.1%; **Table 2**).
207 Median (IQR) follow-up after the mRNA-1273.214 booster was 117 (109-130) days and the

208 median time between dose 2 of mRNA-1273 primary series and mRNA-1273.214 booster was
209 7.9 (7.0-8.3) months.

210

211 **Safety**

212 Overall, 382 participants (70.9%) reported ≥ 1 SAR within 7 days after booster
213 vaccination (**Figure S3**). Most SARs were grade 1 or 2 with no grade 4 events reported. Pain
214 (47.3%) was the most commonly reported local SAR; irritability/crying (53.2%), fatigue
215 (33.3%), and loss of appetite (22.3%) were the most commonly reported systemic SARs. Fever
216 ($\geq 38^\circ\text{C}/100.4^\circ\text{F}$) was reported by 41 participants (7.6%); grade 3 fever was reported by 5
217 participants (0.9%), all in the 2-to-5-year age group. Median (range) time of SAR onset was 1.0
218 (1.0-7.0) day and duration was 2.0 (1.0-14.0) days after booster.

219 Unsolicited AEs were reported by 22.3% of participants within 28 days after booster
220 (**Table S5**); 14 (2.6%) were considered vaccine-related. The most reported unsolicited AE was
221 upper respiratory tract infection (5.8%) and the most common unsolicited AEs considered
222 vaccine-related were diarrhea, vomiting, dermatitis, and urticaria (0.4% each). One participant
223 (0.2%) experienced an AESI considered vaccine-related 1 day after booster (erythema
224 multiforme, mild); of note, topical silver sulfadiazine was used for the treatment of bacterial
225 folliculitis previously by this participant. No SAEs, fatal events, or study discontinuations due to
226 AEs occurred within 28 days following booster. Five SAEs and an additional AESI occurred up
227 to the data cutoff, none of which were considered vaccine-related.

228

229 **Immunogenicity**

230 In the primary analysis (PPIS-Neg), booster vaccination induced nAb responses against
231 BA.1 that were superior to those following mRNA-1273 primary series in KidCOVE (**Figure**
232 **3A**). The observed nAb GMCs (95% CI) against BA.1 were 822.0 (737.4-916.5) after mRNA-
233 1273.214 booster and 65.7 (60.6-71.3) after dose 2 of mRNA-1273, respectively; the estimated
234 GMR was 12.5 (95% CI, 11.0-14.3), meeting the pre-specified superiority criterion.
235 Seroresponse rate against BA.1 relative to pre-dose 1 was 99.7% (95% CI, 98.1-100.0) after
236 mRNA-1273.214 booster and 86.1% (95% CI, 81.1-90.2) after mRNA-1273 primary series
237 (**Figure 3B**). The SRR difference was 13.6% (95% CI, 9.7-18.5), meeting the pre-specified non-
238 inferiority criterion.

239 Neutralizing antibody responses against D614G after booster vaccination were non-
240 inferior to those induced by mRNA-1273 primary series in KidCOVE (**Figure 3A**). Among the
241 PPIS-Neg, observed nAb GMCs (95% CI) against D614G were 4873.3 (4453.6-5332.5) and
242 1559.4 (1459.2-1666.6) after mRNA-1273.214 booster and mRNA-1273 primary series,
243 respectively. The estimated GMR of 3.1 (95% CI, 2.8-3.5) met the pre-specified non-inferiority
244 criterion. SRRs relative to pre-dose 1 were 100.0% (95% CI, 98.7-100.0) and 99.5% (95% CI,
245 98.4-99.9) for mRNA-1273.214 boosted participants and mRNA-1273 primary series recipients,
246 respectively (**Figure 3B**). The SRR difference of 0.5% (95% CI, -0.8 to -1.6) met the pre-
247 specified non-inferiority criterion.

248

249 Discussion

250 The omicron-BA.1 variant-containing vaccine (mRNA-1273.214), administered as a 2-
251 dose primary series (25 µg) or a booster (10 µg), had an acceptable safety profile with no new
252 safety concerns in children aged 6 months to 5 years. Compared to mRNA-1273 primary series,
253 elicited nAb responses were superior against BA.1 and non-inferior against D614G. Overall,
254 these interim findings are consistent with current data on variant-containing vaccination in
255 adults. This study is among the first to demonstrate the safety and immunogenicity of a variant-
256 containing COVID-19 vaccine for use as a primary series and booster in pediatric populations,
257 serving as a model of this approach in children.

258 The safety profile of mRNA-1273.214 as a primary series and booster dose was
259 consistent with the mRNA-1273 primary series in this age group.⁷ Unsolicited AEs were
260 generally reflective of common pediatric illnesses, and there were no vaccine-related SAEs or
261 severe AEs. Reactogenicity profiles of the primary series and booster were characterized by
262 mild-to-moderate, transient reactogenicity across age cohorts, with few grade 3, and no grade 4
263 reactions observed. Overall, no new safety concerns were identified, and both the primary series
264 and booster had an acceptable reactogenicity profile in children aged 6 months to 5 years.

265 An omicron-BA.4/BA.5 variant-containing vaccine (mRNA-1273.222) is currently
266 authorized in the United States as a 2-dose primary series in children aged 6 months to 5 years,¹¹
267 ¹⁷ as this population, and younger children in particular, have lower SARS-CoV-2 seropositivity
268 than older age groups.¹⁸ Development of variant-containing formulations suitable for primary
269 vaccination in children is a necessary response to an anticipated reduction in seropositivity
270 among children, with aging-in of new birth cohorts paired with continued SARS-CoV-2
271 evolution. In this study, the effectiveness of a mRNA-1273.214 primary series in children was

272 inferred from meeting pre-specified success criteria for immunobridging to age-matched
273 historical controls who received mRNA-1273 primary series in KidCOVE.⁷ Overall, these data
274 suggest that variant-containing primary vaccination will potentially better protect young children
275 as SARS-CoV-2 variants evolve and establishes a proof of principle for this approach among
276 children.

277 The omicron-BA.4/BA.5 variant-containing vaccine is also authorized in the United
278 States as a booster dose in children aged 6 months to 5 years.^{11, 17} In this study, evaluation of an
279 omicron-BA.1 variant-containing vaccine (mRNA-1273.214) booster after completing the
280 original primary series provided insights into variant responses in children. Effectiveness of the
281 booster was inferred based on meeting pre-specified success criteria for immunobridging to
282 mRNA-1273 primary series recipients in KidCOVE.⁷ Our findings in young children are
283 consistent with those in adults, with omicron-containing booster vaccination eliciting superior
284 immune responses against vaccine-matched BA.1 or BA.4/BA.5.^{12, 13} Moreover, a BA.4/BA.5-
285 containing booster (mRNA-1273.222) in adults induced nAbs against BQ.1.1 and XBB.1
286 subvariants, highlighting the breadth afforded by variant-containing formulations.^{14, 19} Other
287 studies of mRNA-based COVID-19 vaccines have shown persistence of germinal center B cell
288 responses, enabling robust humoral immunity against SARS-CoV-2.^{20, 21} Additionally, COVID-
289 19 incidence rates trended lower among mRNA-1273.214 booster recipients than mRNA-1273
290 booster recipients in a clinical trial of individuals aged ≥ 16 years.¹³ Notably, real-world studies
291 showed variant-containing boosters provide additional protection against symptomatic
292 infection²² or COVID-19–associated hospitalization²³ among adults who received ≥ 2 doses of a
293 vaccine targeting the ancestral strain. Overall, the observed benefits of booster vaccination in
294 adults are expected to extend to young children. Further, given that efficacy of the original

295 vaccine declined with the emergence of a new immune-evading variant,⁶ ongoing booster
296 vaccinations would only be anticipated when vaccine formulation is updated to better match
297 emergent SARS-CoV-2 variants.

298 Trial limitations include the open-label study design and use of a non-contemporaneous
299 comparative cohort. The inclusion of a placebo-controlled or an active-controlled arm was
300 precluded due to established COVID-19 vaccination recommendations in this age group.
301 Additionally, this interim analysis presents data from a small population of Part 1 participants
302 who had a higher percentage of baseline SARS-CoV-2–positive status than previously observed
303 among KidCOVE participants, which could potentially impact immunogenicity comparisons. All
304 participants were included for the primary analysis since the cohort is reflective of the serologic
305 status of the unvaccinated population. When analyses were limited to baseline SARS-CoV-2–
306 negative participants, substantially higher nAb concentrations were still observed against BA.1
307 after mRNA-1273.214 versus mRNA-1273 vaccination. However, nAb concentrations against
308 ancestral SARS-CoV-2 among baseline SARS-CoV-2 negative participants were lower after
309 mRNA-1273.214 versus mRNA-1273. But as SARS-CoV-2 has evolved, data demonstrate that a
310 variant-containing vaccine more closely matched to circulating strains is more beneficial than the
311 original vaccine.¹³ Further studies of variant-containing vaccines in children are ongoing. A
312 phase 2 trial evaluating the safety, tolerability, and effectiveness of mRNA-1273.214 among
313 infants aged 12 weeks to 5 months is recruiting (NCT05584202).

314

315 **Conclusion**

316 In children aged 6 months to 5 years, a 2-dose 25- μ g primary series and 10- μ g booster
317 dose of mRNA-1273.214 were immunogenic against BA.1 and D614G, with a comparable safety

318 profile to mRNA-1273 primary vaccination. These findings are among the first to demonstrate
319 the safety and inferred effectiveness of a variant-containing COVID-19 vaccine in pediatric
320 populations and support a 2-dose schedule for previously unvaccinated children with an
321 additional dose when the formulation is successively updated. Further studies are needed to
322 assess the effectiveness and durability of variant-containing COVID-19 vaccines in children.

323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354

Funding/Support

This work was supported by Moderna, Inc.

Acknowledgments

We thank the participants and their families for their involvement in the trial, as well as the staff at the trial sites for implementing the protocol. Medical writing and editorial assistance were provided by Jared Mackenzie, PhD, Kate Russin, PhD, and Lindsey Kirkland, PhD, of MEDiSTRAVA in accordance with Good Publication Practice guidelines, funded by Moderna, Inc., and under the direction of the authors.

Conflicts of Interest Disclosures (includes financial disclosures)

AD, RP, KH, BG, WZ, WD, HZ, SSG, JMM, and RD are employees of Moderna, Inc., and hold stock/stock options in the company. AY, KS and BJK are consultants for Moderna, Inc.

Data Sharing Statement

As the trial is ongoing, access to patient-level data presented in the article (immunogenicity, safety, and reactogenicity) and supporting clinical documents by qualified external researchers who provide methodologically sound scientific proposals may be available upon reasonable request and subject to review once the trial is complete. Such requests can be made to Moderna, Inc., 200 Technology Square, Cambridge, MA 02139. A materials transfer and/or data access agreement with the sponsor will be required for accessing shared data. All other relevant data are presented in the paper.

Author Contributions

A.D., R.B., K.A., M.T., K.H., K.S., W.D., H.Z., S.S.G., J.M.M., F.P., and R.D. conceived and designed the current study. A.D., R.B., K.A., C.G., R.A.C., M.T., R.P., B.K., K.S., A.Y., B.G., W.Z., W.D., H.Z., S.S.G., J.M.M., F.P., and R.D. carried out analysis and interpretation of data and take responsibility for the integrity of the data and accuracy of the data analysis. All authors critically reviewed the paper for important intellectual content and approved the final draft of the manuscript.

355 **References**

- 356 1. Watanabe A, Kani R, Iwagami M, Takagi H, Yasuhara J, Kuno T. Assessment of
357 Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A
358 Systematic Review and Meta-analysis. *JAMA Pediatr.* 2023.
- 359 2. World Health Organization. Tracking SARS-CoV-2 variants.
360 <https://www.who.int/activities/tracking-SARS-CoV-2-variants>. Published 2022.
361 Accessed 3 November, 2022.
- 362 3. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al.
363 Protection and waning of natural and hybrid immunity to SARS-CoV-2. *N Engl J Med.*
364 2022;386(23):2201-2212.
- 365 4. The World Health Organization. Weekly Epidemiological Update on COVID-19 18-8
366 March 2023. [https://www.who.int/publications/m/item/weekly-epidemiological-update-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19--8-march-2023)
367 [on-covid-19--8-march-2023](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19--8-march-2023). Published 2023. Accessed 15 March 2023.
- 368 5. Collie S, Nayager J, Bamford L, Bekker LG, Zylstra M, Gray G. Effectiveness and
369 durability of the BNT162b2 vaccine against omicron sublineages in South Africa. *N Engl*
370 *J Med.* 2022;387(14):1332-1333.
- 371 6. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of
372 mRNA-1273 against SARS-CoV-2 omicron and delta variants. *Nat Med.*
373 2022;38(5):1063-1071.
- 374 7. Anderson EJ, Creech CB, Berthaud V, Piramzadian A, Johnson KA, Zervos M, et al.
375 Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age. *N Engl J Med.*
376 2022;387(18):1673-1687.
- 377 8. Creech CB, Anderson E, Berthaud V, Yildirim I, Atz AM, Melendez Baez I, et al.
378 Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 Years of age. *N Engl J*
379 *Med.* 2022;386(21):2011-2023.
- 380 9. Fleming-Dutra KE, Ciesla AA, Roper LE, Smith ZR, Miller JD, Accorsi EK, et al.
381 Preliminary estimates of effectiveness of monovalent mRNA vaccines in preventing
382 symptomatic SARS-CoV-2 infection among children aged 3-5 years - increasing
383 community access to testing program, United States, July 2022-February 2023. *MMWR*
384 *Morb Mortal Wkly Rep.* 2023;72(7):177-182.
- 385 10. Flaxman S, Whittaker C, Semenova E, Rashid T, Parks RM, Blenkinsop A, et al.
386 Assessment of COVID-19 as the underlying cause of death among children and young
387 people aged 0 to 19 years in the US. *JAMA Netw Open.* 2023;6(1):e2253590.
- 388 11. U.S. Food and Drug Administration. Fact Sheet for Healthcare Providers Administering
389 Vaccine: Emergency Use Authorization of Moderna COVID-19 Vaccine, Bivalent
390 (Original and Omicron BA.4/BA.5).
391 [https://assets.modernatx.com/m/17d17b09d117ca22/original/EUA-COVID-19-Vaccine-](https://assets.modernatx.com/m/17d17b09d117ca22/original/EUA-COVID-19-Vaccine-Bivalent-Fact-Sheet-for-Vaccine-Providers-6m.pdf)
392 [Bivalent-Fact-Sheet-for-Vaccine-Providers-6m.pdf](https://assets.modernatx.com/m/17d17b09d117ca22/original/EUA-COVID-19-Vaccine-Bivalent-Fact-Sheet-for-Vaccine-Providers-6m.pdf). Updated April 2023.
- 393 12. Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, et al. A bivalent
394 omicron-containing booster vaccine against Covid-19. *N Engl J Med.*
395 2022;387(14):1279-1291.
- 396 13. Lee IT, Cosgrove CA, Moore P, Bethune C, Nally R, Bula M, et al. A randomized trial
397 comparing omicron-containing boosters with the original Covid-19 vaccine mRNA-1273.
398 *medRxiv.* 2023:2023.2001.2024.23284869.

- 399 14. Chalkias S, Whatley J, Eder F, Essink B, Khetan S, Bradley P, et al. Safety and
400 Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19. *medRxiv*.
401 2022:2022.2012.2011.22283166.
- 402 15. Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation
403 of mRNA-1273 SARS-CoV-2 vaccine in adolescents. *NEJM*. 2021;385(24):2241-2251.
- 404 16. Bonhomme ME, Bonhomme CJ, Strelow L, Chaudhari A, Howlett A, Breidenbach C, et
405 al. Robust validation and performance comparison of immunogenicity assays assessing
406 IgG and neutralizing antibodies to SARS-CoV-2. *PLoS One*. 2022;17(2):e0262922.
- 407 17. U.S. Food and Drug Administration. Emergency Use Authorization for Moderna
408 COVID-19 Vaccine Review Memo 04182023.
409 <https://www.fda.gov/media/167306/download>. Updated April 2023.
- 410 18. Naeimi R, Sepidarkish M, Mollalo A, Parsa H, Mahjour S, Safarpour F, et al. SARS-
411 CoV-2 seroprevalence in children worldwide: a systematic review and meta-analysis.
412 *EClinicalMedicine*. 2023;56:101786.
- 413 19. Moderna. Moderna COVID-19 Bivalent Vaccines Primary Series and Booster, Vaccines
414 and Related Biological Products Advisory Committee.
415 <https://www.fda.gov/media/164810/download>. Updated January 26 2023.
- 416 20. Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. SARS-CoV-
417 2 mRNA vaccines induce persistent human germinal centre responses. *Nature*.
418 2021;596(7870):109-113.
- 419 21. Alsoussi WB, Malladi SK, Zhou JQ, Liu Z, Ying B, Kim W, et al. SARS-CoV-2
420 Omicron boosting induces de novo B cell response in humans. *Nature*. 2023.
- 421 22. Link-Gelles R, Ciesla AA, Fleming-Dutra K-E, Smith ZR, Britton A, Wiegand RE, et al.
422 Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2
423 Infection — Increasing Community Access to Testing Program, United States,
424 September–November 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(5152):1526–1530.
- 425 23. Tenforde MW, Weber ZA, Natarajan K, Klein NP, Kharbanda AB, Stenehjem E, et al.
426 Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-
427 associated emergency department or urgent care encounters and hospitalizations among
428 immunocompetent adults - VISION Network, nine states, September-November 2022.
429 *MMWR Morb Mortal Wkly Rep*. 2022;71(5152):1616-1624.

430

431

432 **Table 1. Participant Demographics in Part 1 (mRNA-1273.214 Primary Series; Safety Set)**

	Part 1 Participants (N=179)
Mean age, years (SD)	2.6 (1.4)
Median age, years (IQR; min-max)	3.0 (1.0-3.0; 0.5-5.0)
Male, n (%)	98 (54.7)
Race, n (%)	
White	117 (65.4)
Black	46 (25.7)
Asian	5 (2.8)
American Indian or Alaska Native	1 (0.6)
Native Hawaiian or Other Pacific Islander	0
Multiracial	8 (4.5)
Other	2 (1.1)
Unknown or not reported	0
Ethnicity, n (%)	
Hispanic or Latino	21 (11.7)
Not Hispanic or Latino	158 (88.3)
Unknown or not reported	0
Baseline SARS-CoV-2 infection, n (%) ^a	
Positive	113 (63.1)
Negative	42 (23.5)
Missing	24 (13.4)

433 IQR, interquartile range; RT-PCR, reverse transcription-polymerase chain reaction.

434 ^aBaseline SARS-CoV-2 status was categorized as positive if there was immunologic or virologic
435 evidence of prior COVID-19, defined as positive RT-PCR test or positive Elecsys result on or
436 before Day 1. Negative was defined as negative RT-PCR test and negative Elecsys result on or
437 before Day 1.

438

439 **Table 2. Participant Demographics in Part 2 (mRNA-1273.214 Booster; Safety Set)**

	Part 2 Participants (N=539)
Mean age, years (SD)	2.7 (1.3)
Median age, years (IQR; min-max)	3.0 (2.0-4.0; 0.9-5.0)
Male (%)	276 (51.2)
Race, n (%)	
White	437 (81.1)
Black	17 (3.2)
Asian	26 (4.8)
American Indian or Alaska Native	0
Native Hawaiian or Other Pacific Islander	2 (0.4)
Multiracial	52 (9.6)
Other	0
Unknown	1 (0.2)
Not reported	4 (0.7)
Ethnicity, n (%)	
Hispanic or Latino	59 (10.9)
Not Hispanic or Latino	476 (88.3)
Unknown	2 (0.4)
Not reported	2 (0.4)
Pre-booster SARS-CoV-2 infection, n (%) ^a	
Positive	153 (28.4)
Negative	331 (61.4)
Missing	55 (10.2)

440 IQR, interquartile range; RT-PCR, reverse transcription-polymerase chain reaction.

441 ^aPre-booster SARS-CoV-2 status was categorized as positive if there was immunologic or

442 virologic evidence of prior COVID-19, defined as positive RT-PCR test or positive Elecsys

443 result on or before booster dose Day 1. Negative was defined as negative RT-PCR

444 test and negative Elecsys result on or before booster dose Day 1.

445 **Figure Legends**

446 **Figure 1.** Participant disposition in Part 1 (A) and Part 2 (B).

447 PPIS, per-protocol immunogenicity set; PPIS-Neg, per-protocol immunogenicity set-negative.

448

449 **Figure 2.** Serum neutralizing antibodies against BA.1 (A) and D614G (B) after mRNA-1273.214

450 primary series or mRNA-1273 primary series in Part 1.

451 Pseudovirus nAbs at BL and at 28 days after dose 2 (day 57) are shown for participants in the

452 PPIS and by baseline SARS-CoV-2 status. No prior SARS-CoV-2 infection was defined as

453 negative RT-PCR test and negative Elecsys result on or before Day 1. Prior SARS-CoV-2

454 infection was indicated by a positive RT-PCR test or positive Elecsys result on or before Day 1.

455 Overall: mRNA-1273.214, n=71; mRNA-1273, n=632; no prior infection: mRNA-1273.214,

456 n=26; mRNA-1273, n=590; prior infection: mRNA-1273.214, n=45; mRNA-1273, n=42.

457 Antibody values below the LLOQ were replaced by 0.5 x LLOQ. Values greater than the ULOQ

458 were replaced by the ULOQ if actual values were not available. LLOQs were 8 (BA.1) or 10

459 (D614G); ULOQs were 41984 (BA.1) or 4505600 (D614G).

460 BL, baseline; CI, confidence interval; GMC, geometric mean concentration; GMR, geometric

461 mean ratio; LLOQ, lower limit of quantification; nAb, neutralizing antibody; PPIS, per-protocol

462 immunogenicity set; RT-PCR, reverse transcription-polymerase chain reaction; ULOQ, upper

463 limit of quantification.


464

465 **Figure 3.** Serum neutralizing antibodies against BA.1 and D614G (A) and seroresponse rates (B)
466 after mRNA-1273.214 booster or mRNA-1273 primary series vaccination in Part 2
467 Pseudovirus nAbs against BA.1 or D614G were measured before the mRNA-1273.214 booster
468 dose (pre-booster) and at 28 days after the booster dose (Day 29) among participants in the PPIS,
469 as well as before the mRNA-1273 primary series (pre-dose 1) and 28 days after the mRNA-1273
470 primary series dose 2 (Day 57). No prior SARS-CoV-2 infection was defined as negative RT-
471 PCR test and negative Elecsys result on or before Day 1. Prior SARS-CoV-2 infection was
472 indicated by a positive RT-PCR test or positive Elecsys result on or before Day 1. No prior
473 infection: mRNA-1273.214 booster, n=299; mRNA-1273, n=590; prior infection: mRNA-
474 1273.214 booster, n=136; mRNA-1273, n=42. Serologic response was defined as an increase in
475 antibody levels from below the LLOQ at baseline to ≥ 4 times the LLOQ, or a ≥ 4 -fold rise if
476 baseline was equal or above the LLOQ. Antibody values below the LLOQ were replaced by 0.5
477 x LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not
478 available. LLOQs were 8 (BA.1) or 10 (D614G); ULOQs were 41984 (BA.1) or 4505600
479 (D614G).

480 CI, confidence interval; GMC, geometric mean concentration; GMR, geometric mean ratio;
481 LLOQ, lower limit of quantification; nAb, neutralizing antibody; PPIS, per-protocol
482 immunogenicity set; RT-PCR, reverse transcription-polymerase chain reaction; ULOQ, upper
483 limit of quantification.

484 **Figures**



485 **Figure 1.**



486


487

488 **Figure 2.**




490 **Figure 3.**

A



B



491